Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED

Microculture Kinetic (MiCK) Apoptosis Test Results With Drug Treatment Results in Cancer Patients

NCT00901264 · View on ClinicalTrials.gov ↗

Study Summary

The purpose of this study is to correlate the results of the MICK assay with short- and long-term results of treatments in cancer patients and evaluate the role of the MiCK assay in guiding chemotherapy of cancer patients.

Conditions Studied

Study Locations (11)

Tennessee

  • DiaTech Oncology — Brentwood
  • Cumberland Medical Center — Crossville
  • Middle Tennessee Medical Center — Murfreesboro
  • Baptist Hospital — Nashville
  • Nashville Oncology Associates — Nashville
  • St. Thomas Research Institute, LLC — Nashville
  • Tennessee Breast Specialists — Nashville
  • Tennessee Toracic Surgical Specialists — Nashville

California

  • Wilshire Oncology Medical Group, Inc — La Verne

Florida

  • Tampa General Hospital — Tampa

Quebec

  • DiaTech Oncology — Montreal

Trial Details

FieldValue
Enrollment Target 300 participants
Start Date 2008-12
Est. Completion 2012-11

Sponsor

Pierian Biosciences

2 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00901264

The ClinicalTrials.gov registry entry for NCT00901264 describes a study currently listed as completed. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pierian Biosciences, which has 2 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Cancer appearing as the primary indexed condition, and to 0 interventions. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT00901264 reports 11 study locations spanning 4 distinct geographic areas — top geographies include Tennessee, California, Florida. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT00901264 about?

NCT00901264 is a clinical study titled "Microculture Kinetic (MiCK) Apoptosis Test Results With Drug Treatment Results in Cancer Patients". The purpose of this study is to correlate the results of the MICK assay with short- and long-term results of treatments in cancer patients and evaluate the role of the MiCK assay in guiding chemotherapy of cancer patients.

What is the current status of trial NCT00901264?

This trial is currently completed. The enrollment target is 300 participants. The study started on 2008-12. Estimated completion is 2012-11.

What conditions does trial NCT00901264 study?

This clinical trial studies the following conditions: Cancer. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

Who is sponsoring clinical trial NCT00901264?

This trial is sponsored by Pierian Biosciences, which has 2 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT00901264 being conducted?

This trial has 11 study locations across California, Florida, Tennessee, Quebec. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial